Plasmodium falciparum induces T cell tolerance that is associated with decreased disease severity upon reinfection

Search results

• Finished

  MultiViVax: Development of Effective Vaccines against Multiple Lifecycle Stages of Plasmodium vivax malaria

  Rowe, A. (Principal Investigator) & Spence, P. (Co-investigator)

  European Commission

  1/01/17 → 31/12/22

  Project: Research

  • Infection 100%
  • T-Cell Tolerance 50%
  • Plasmodium falciparum 50%
  • Plasmodium vivax 50%
  • Pathogen Load 29%

• Wellcome Trust Four-Year PhD Studentship

  Matthews, K. (Principal Investigator) & Woolhouse, M. (Co-investigator)

  Wellcome Trust (Rcl)

  1/10/16 → 1/04/21

  Project: Research

  • T-Cell Tolerance 100%
  • Plasmodium falciparum 100%
  • Infection 100%
  • Memory B Cell 50%
  • Effector Cell 50%

• Wellcome Trust Four-Year PhD Studentship (Mr Florian Bach)

  Matthews, K. (Principal Investigator) & Woolhouse, M. (Co-investigator)

  UK-based charities

  1/10/16 → 1/04/21

  Project: Research

  • Infection 100%
  • Plasmodium vivax 60%
  • T Cell Activation 40%
  • Systemic Inflammation 30%
  • Parasitemia 27%

• Monocyte & macrophage function in malaria disease severity

  Spence, P. (Principal Investigator)

  UK-based charities

  1/11/15 → 31/01/22

  Project: Research

  • Infection 100%
  • Plasmodium vivax 40%
  • Plasmodium falciparum 29%
  • T Cell Activation 26%
  • Pathogen Load 21%

• Future-Proofing the sustainability of the MRC high throughput sequencing hub in Scotland

  Blaxter, M. (Principal Investigator)

  MRC

  1/10/12 → 30/09/14

  Project: Research

  • Infection 100%
  • Genomics 88%
  • Gene Expression 72%
  • Transcriptome 63%
  • Escherichia coli 61%

• NERC Molecular Genetics Facility core grant

  Blaxter, M. (Principal Investigator)

  NERC

  1/04/08 → 31/03/11

  Project: Research

  • Infection 100%
  • Gene Expression 87%
  • Genomics 83%
  • Escherichia coli 79%
  • Ribonucleic Acid 67%